NextVivo is an ambitious start-up company, located in Stanford Research Park. We are working to leverage the power of the breakthrough technology of human derived immune organoids, invented by our co-founders Mark Davis and Calvin Kuo at Stanford University. We are focused on using this immune-competent organoid platform to develop novel drugs and cell therapies to fight human diseases, including cancer, infectious disease, and autoimmune disorders.
Company Details
- Employees
- 2
- Address
- 3160 Porter Dr, Palo Alto,california 94304,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://nextvivo.bio
- HQ
- Palo Alto, California
Nextvivo Questions
Nextvivo's website is http://nextvivo.bio
Nextvivo's LinkedIn profile is https://www.linkedin.com/company/nextvivo
Nextvivo has
2 employees.
View email and phone details for 2
employees at Nextvivo.
Nextvivo's industry is
Biotechnology Research
Nextvivo's top competitors are
Bighat Biosciences,
Genista Biosciences,
Prellis Biologics,
Parvus Therapeutics Inc,
3d-Hub-O,
Zeneuroid,
Inograft Biotherapeutics, Inc.,
Avail Bio,
Flashpoint Therapeutics,
Sonoma Biotherapeutics, Inc..
Nextvivo's categories are Biotechnology Research
